Literature DB >> 12915071

Prevention and treatment of motor fluctuations.

Fabrizio Stocchi1.   

Abstract

The symptoms of Parkinson's disease can become increasingly difficult to control as the disease advances, particularly with the development of motor complications, such as end-of-dose wearing-off and dyskinesias, following long-term therapy. At this stage, the patient is frequently referred to a Parkinson's disease specialist for advice on the management of their disease. In this review we provide an overview of the Parkinson's disease specialist's strategies for coping with such problems. This includes strategy to prevent or delay motor fluctuations and the concept of the long duration response. The paper also includes establishing the optimum and most rational levodopa treatment schedule, improving levodopa absorption, use of COMT-inhibition, the addition of oral dopaminergic agonists, and the use of subcutaneous injections or infusions of apomorphine or lisuride. Finally, we highlight the increasing importance of treatment strategies that stimulate dopamine receptors in a more continuous, less pulsatile manner as a way of reducing the risk of developing treatment-associated motor complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915071     DOI: 10.1016/s1353-8020(03)00021-x

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

1.  Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?

Authors:  Martin Bareš; Irena Rektorová; Robert Jech; Kateřina Farníková; Jan Roth; Evžen Růžička; Petr Kaňovský; Ivan Rektor; Tomáš Pavlík; Leona Uhlířová; Jaroslav Vydlák
Journal:  J Neural Transm (Vienna)       Date:  2011-07-17       Impact factor: 3.575

2.  Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study.

Authors:  Richard M Trosch; Dee Silver; Peter B Bottini
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Design of an N-methylated peptide inhibitor of alpha-synuclein aggregation guided by solid-state NMR.

Authors:  Jillian Madine; Andrew J Doig; David A Middleton
Journal:  J Am Chem Soc       Date:  2008-05-30       Impact factor: 15.419

Review 4.  Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

Authors:  Michael J Beckstead; Rebecca D Howell
Journal:  Exp Neurol       Date:  2021-03-20       Impact factor: 5.620

5.  L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.

Authors:  Fabrizio Stocchi; Laura Vacca; Paola Grassini; Stephen Pawsey; Holly Whale; Stefano Marconi; Margherita Torti
Journal:  Parkinsons Dis       Date:  2015-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.